Axsome Therapeutics AXSM Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $305.11M+1.4% | $322.93M+2.4% | $325.27M-0.6% | $303.02M-4.0% | $300.91M-9.2% | ||
| $251.06M+55.6% | $224.46M+58.1% | $196.51M+58.4% | $198.83M+65.2% | $161.4M+59.1% | ||
| $31.52M+93.1% | $27.94M+77.6% | $23.77M+66.7% | $18.44M+21.2% | $16.32M+4.7% | ||
| $23.52M+47.0% | $13.65M+14.0% | $19.79M+47.6% | $16.34M+38.4% | $16.01M+33.0% | ||
| $611.21M+23.6% | $588.99M+21.4% | $565.34M+18.0% | $536.62M+15.9% | $494.63M+7.4% | ||
| $567K-26.6% | $562K-3.8% | $605K-11.4% | $667K-7.9% | $773K-4.8% | ||
| $20.01M-14.1% | $20.86M+287% | $21.65M+278% | $22.47M+270% | $23.29M+263% | ||
| $12.04M0.0% | $12.04M0.0% | $12.04M0.0% | $12.04M0.0% | $12.04M0.0% | ||
| $38.95M-14.1% | $40.52M-13.6% | $42.13M-13.1% | $43.73M-12.7% | $45.32M-12.3% | ||
| $713.61M+19.6% | $689.81M+21.3% | $669.25M+19.2% | $639.79M+16.7% | $596.67M+9.3% | ||
| $106.7M+24.6% | $65.54M-9.0% | $54.23M-15.6% | $91.63M+49.4% | $85.66M+59.2% | ||
| $70M— | —— | —— | —— | —— | ||
| $628K+38.3% | $434K-76.3% | $736K-54.8% | $337K-76.3% | $454K-60.6% | ||
| $3.19M+75.8% | $2.55M+79.1% | $2.5M— | $2.01M— | $1.82M— | ||
| $439.21M+80.1% | $378.84M+64.6% | $360.29M+83.6% | $342.1M+83.4% | $243.91M+69.3% | ||
| $117.85M-35.0% | $117.75M-34.8% | $117.64M-34.6% | $117.54M-34.5% | $181.38M+1.5% | ||
| $22.39M-6.4% | $23.18M+283% | $23.04M+258% | $23.62M+246% | $23.91M+229% | ||
| $9.04M+64.4% | $6.75M+54.7% | $7.18M— | $5.81M— | $5.5M— | ||
| $23.01M-5.5% | $23.62M+200% | $23.78M+195% | $23.96M+191% | $24.36M+190% | ||
| $5.84M+58.8% | $4.21M+42.9% | $4.68M— | $3.79M— | $3.68M— | ||
| $659.02M+21.3% | $601.51M+17.6% | $595.52M+27.1% | $566.71M+27.2% | $543.47M+35.3% | ||
| $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $1.43B+15.4% | $1.39B+18.2% | $1.35B+18.4% | $1.3B+20.0% | $1.24B+17.9% | ||
| -$1.37B-15.9% | -$1.31B-16.3% | -$1.28B-21.9% | -$1.23B-25.1% | -$1.18B-30.8% | ||
| $54.59M+2.6% | $88.3M+54.9% | $73.73M-20.6% | $73.08M-29.0% | $53.21M-63.1% | ||
| $713.61M+19.6% | $689.81M+21.3% | $669.25M+19.2% | $639.79M+16.7% | $596.67M+9.3% | ||
| $20.01M-14.1% | $20.86M+287% | $21.65M+278% | $22.47M+270% | $23.29M+263% | ||
| $38.95M-14.1% | $40.52M-13.6% | $42.13M-13.1% | $43.73M-12.7% | $45.32M-12.3% | ||
| $20.01M-14.1% | $20.86M+287% | $21.65M+278% | $22.47M+270% | $23.29M+263% | ||
| $30.83M+49.6% | $26.84M+44.8% | $27.48M+78.6% | $24.25M+49.2% | $20.61M+44.3% | ||
| $20.01M-14.1% | $20.86M+287% | $21.65M+278% | $22.47M+270% | $23.29M+263% | ||
| $250.73M+68.1% | $232.85M+57.3% | $225.63M+84.7% | $170.9M+46.4% | $149.2M+80.4% | ||
| $73.73M-18.6% | $77.54M-15.4% | $89.87M+8.3% | $79.66M+14.4% | $90.59M+29.4% | ||
| $219.9M+4.1% | $218.11M+13.0% | $218.6M+13.7% | $217.31M+13.3% | $211.23M+11.5% | ||
| $1.43B+15.4% | $1.39B+18.2% | $1.35B+18.4% | $1.3B+20.0% | $1.24B+17.9% | ||
| $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| $3.19M+75.8% | $2.55M+79.1% | $2.5M— | $2.01M— | $1.82M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Axsome Therapeutics's total assets?
- Axsome Therapeutics (AXSM) holds $713.6M in total assets, up 19.6% year over year.
- How much debt does Axsome Therapeutics have?
- Axsome Therapeutics carries $219.9M in total debt against $54.6M of shareholders' equity, a debt-to-equity ratio of 4.03.
- How much cash does Axsome Therapeutics have?
- Axsome Therapeutics holds $305.1M in cash and equivalents.
- Can Axsome Therapeutics cover its short-term obligations?
- Its current ratio is 1.39 — current assets exceed current liabilities.
- Where does Axsome Therapeutics's balance sheet data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
